Observational studyMedicine2026
The evolving disease burden of lung cancer (2014-2023) in Qingdao, China: An observational trend study with projections.
Observational study in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Long-term trend studies on the burden of lung cancer in Qingdao, a coastal city in China, remain limited. Therefore, this study aimed to assess temporal trends in the burden of lung cancer over 10 years and to project future patterns through 2028. Based on lung cancer incidence and mortality data obtained from the Qingdao Center for Disease Control and Prevention for the period 2014 to 2023, we calculated the age-standardized incidence rates by world standard population (ASIRW), age-standardized mortality rates by world standard population (ASMRW), and age-standardized years of life lost rates by world standard population (ASYRW) per 1,00,000 population. Temporal trends were assessed through Joinpoint regression analysis to estimate average annual percentage changes (AAPC). The GM (1,1) model was used for exploratory forecasting of lung cancer burden trends. In Qingdao, a statistically significant increasing trend was observed for ASIRW in females, with an AAPC of 3.48% (95% CI: 0.97 to 6.30, P = .004). The overall trend of ASMRW decreased with the AAPC of -2.11% (95% CI: -2.70 to -1.54, P < .001). Similarly, the ASMRW exhibited statistically significant declining trends in both males and females, with the AAPC of -1.59% (95% CI: -2.43 to -0.78, P < .001) and -2.92% (95% CI: -4.26 to -1.64, P < .001), respectively. The ASYRW showed trends consistent with that of ASMRW. Exploratory projections to 2028 indicated that the ASIRW, ASMRW, and ASYRW will generally decline, except for the ASIRW in females. These findings underscore the need for targeted interventions focusing on high-risk populations, particularly specific subgroups of women, while providing descriptive epidemiological evidence to inform future public health surveillance.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.